Plexxikon, Inc. engages in the discovery and development of small molecule pharmaceuticals to treat human disease. The company's products include PLX204 for the treatment of diabetes; PLX4032 for the treatment of melanoma and colorectal cancer; and PLX5568 kinase inhibitors for the treatment of pain, polycystic kidney disease, rheumatoid arthritis, metastatic breast cancer, and renal disease. It develops a portfolio of clinical and preclinical stage programs in various therapeutic areas, including metabolic disease, such as obesity indications; oncology, such as osteolytic metastatic disease; and CNS, such as multiple sclerosis. The company’s portfolio of clinical and preclinical stage programs for other therapeutic areas include inflammation, such as systemic lupus erythematosus, inflammatory bowel disease, and osteoporosis; and cardiovascular, including hypertension and atherosclerosis.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company employs technologies, such as its ArQule Kinase Inhibitor Platform (AKIP) to design and develop drugs. The Company's product is ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase. ARQ 197 is being evaluated as monotherapy and in combination therapy in a Phase II clinical development program that includes trials in Microphthalmia Transcription Factor (MiT) associated tumors, non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma and hepatocellular carcinoma (HCC). The Company has licensed commercial rights to ARQ 197 for human cancer indications to Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) in the United States, Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where it has licensed commercial rights to Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin).

GENOMICA SAU provides genetic identification and molecular diagnostic services. Its services include paternity tests, fornsic genetics technological transfers and laboratory genetic identification for criminal investigation. The firm also offers various diagnostic kits and reagents such as CLART PneumoVir, CLINICAL ARRAYS Metabona and CLINICAL ARRAYS-Papillomavirus. It also provides laboratory installation and technical support services and training courses for laboratory, clinical and forensics professionals. The company was founded in 1990 and is headquartered in Madrid, Spain.

Genomic Health, Inc. (NASDAQ: GHDX) is a provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient's journey, from diagnosis to treatment selection and monitoring. The company is based in Redwood City, California, with European headquarters in Geneva, Switzerland.

Suzhou Kebei Biotechnology Co., Ltd., established on 2009-09-10, Business scope includes licensed projects:Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Production of Class I Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Development of Human Gene Diagnosis and Therapy Technology;Human stem cell technology development and application;R&D and application of cell technology;Medical Research and Experimental Development;Health Consulting Services(Does not include medical services);Conference and Exhibition Services(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Shanghai Sai'an Biomedical Technology Co., Ltd., established on 2010-02-04, Business scope includes biotechnology,Engage in technology development in the field of medical science and technology,technology transfer,Technical Services,technical consulting;Medical Device Sales;Business Consulting. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Shanghai Rigen Biotechnology Co. Ltd. is a company headquartered in China. The firm provides research and development services.

Jiangsu Genuo Biological Technology Co., Ltd. is a Chinese company with domestic subsidiaries. The firm engages in research and development and manufactures drugs.

Shanghai Genuo Biotechnology Co., Ltd., established on 2010-11-19, The scope of business includes research and development of biomedical technology and related products,Provide relevant technical advice,Technical Services,technology transfer,Chemical raw materials and products(Removal of hazardous chemicals,Monitor Chemicals,civilian explosives,precursor chemicals),Research and development of laboratory equipment,Sales,laboratory consumables,Instrumentation,electronic product,Sales of biological reagents for non-clinical diagnosis,Engaged in the import and export of goods and technology. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Shenyang Youjino Biotechnology Co., Ltd., established on 2011-06-27, Business scope includes biological product development and technical consulting;laboratory apparatus,experiment apparatus,Experimental reagent sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments.)

Response Genetics, Inc. is engaged in the research and development of clinical diagnostic tests for cancer. Its platforms include analysis of single biomarkers using the polymerase chain reaction method as well as global gene interrogation using microarray methods from paraffin or frozen tissue specimens. It also provides pharmacogenomic testing services of clinical trial specimens to pharmaceutical companies. The company was founded by David A. Smith and Kathleen Danenberg on September 23, 1999 and is headquartered in Los Angeles, CA.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Wuhan Newster Biotechnology Co., Ltd., established on 2006-01-24, The business scope includes the development of bioengineering and biomedical engineering products,Biotechnology R&D,Transfer and Consulting Services;Bioengineering Equipment Sales.Import and export,Technology Import and Export,Agent import and export(Does not contain goods or technologies that are prohibited or restricted from import and export by the state).

BioMed Valley Discoveries, Inc. is a private company headquartered in Kansas City, MO, that operates as a biotechnology company which develops therapies for cancer, inflammation and infectious disease. It was founded by Saurabh Saha.\nThe company says this about itself: BioMed Valley Discoveries is a clinical stage biotechnology company focused on addressing unmet medical needs in a variety of therapeutic and diagnostic areas. In addition to the ERK inhibitor, BVD's portfolio includes an oncolytic bacteria that has completed enrollment for a Phase I study, a selective phosphoinositide 3-kinase gamma inhibitor in late preclinical testing, and two early-stage antibodies targeting the tumor microenvironment.

Guojiutang Shandong Ejiao Co., Ltd., established on 2012-04-23, Business scope includes general items:Ejiao technology development,consultation service;Purchase and sale of agricultural and sideline products;Realtor.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:Glue production(The validity period is subject to the license);Glue Sales;Production of Chinese Herbal Pieces;Sales of Chinese Herbal Pieces;food production;food sales;(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results)

Established in 1973 in Korea, Hanmi Pharmaceuticals now is one of the top 5 pharmaceutical companies in terms of revenue, and the most R&D focused company with the highest R&D investment for several years. Hanmi has been successful for a few decades with high flexibility, continuously changing its market/development strategy from first generics to IMD & FDC (Incrementally Modified Drug and Fixed Dose Combination) to new drug development including innovative small molecules and biologics. During the period of significant changes, Hanmi made multiple strategic collaboration relationships with multinational companies and biotech companies. Based on the success in 1980s and 1990s, Hanmi started its Chinese operation in 1996 with establishment of Beijing Hanmi. Now, Beijing Hanmi grew as a well-localized and well-settled Chinese company with more than 1,300 staffs including R&D, sales / marketing, and manufacturing experts and significant growth rate higher than 20% every year. Currently, Hanmi and Beijing Hanmi is closely collaborating on various business opportunities and new drug development projects as well as sales and marketing in Chinese territories. As the only Asian company with significant presence both in Korea and China, as the most R&D focused company with number of clinical stage projects with competitiveness, and as the company with open innovation based on multiple development/marketing collaborations, Hanmi is trying to develop and provide differentiated treatment options to patients suffering from various disease.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Guangdong Hybribio Biotech Co., Ltd. engages in the research, development, production, and sale of nucleic acid molecular diagnostic products in China. It also provides on-site technical training and after-sales technical service support. The company was founded by Qiao Zhong Guan on June 13, 2003 and is headquartered in Chaozhou, China.